A Team Of Experts Discovers An Unconventional Side Effect Of Novel Coronavirus For The First Time

Kathleen Kinder
Kathleen Kinder

Updated · Oct 9, 2020

SHARE:

News.Market.us is supported by its audience. When you purchase through links on our site, we may earn an affiliate commission. Learn more.
close
Advertiser Disclosure

At Market.us News, we strive to bring you the most accurate and up-to-date information by utilizing a variety of resources, including paid and free sources, primary research, and phone interviews. Our data is available to the public free of charge, and we encourage you to use it to inform your personal or business decisions. If you choose to republish our data on your own website, we simply ask that you provide a proper citation or link back to the respective page on Market.us News. We appreciate your support and look forward to continuing to provide valuable insights for our audience.

It seems the SARS-CoV-2 virus is planning a coordinated attack on the human body. A new study has revealed another sly symptom of the virus, which might clarify why some COVID19 patients are asymptomatic. Experts have found that the SARS-CoV-2 virus has the ability to bind to a key protein, which is involved in the pain signaling process. Scientists have been trying to neutralize the virus’s spike protein with the help of vaccines, monoclonal antibodies, and other antiviral drugs. Experts have said that pain is a mechanism, which signals that there is something wrong with the body. The COVID19 infection has some symptoms, which involve pain such as headaches and muscle pain. The team of experts has said that the spike protein of the virus acts as a pain reliever, making people feel fine as the pain is suppressed. It explains why some coronavirus positive people show no symptoms of pain.

Scientists from the University of Arizona Health Sciences have said that the SARS-CoV-2 virus obstructs the pain pathway. Experts have told that it might be the reason behind the unrelenting transmission of the virus in the early stages. The data from previous studies show that the spike protein of the virus can attach to neuropilin-1 protein along with the ACE2 receptor, which is used by the virus to infect the cell. Experts have found that a protein called vascular endothelial growth factor-A (VEGF-A) binds to neuropilin-1, and this process results in the symptom of pain. When the SARS-CoV-2 virus obstructs the neuropilin-1, the sequence of the process, which results in pain is blocked.

Many experiments have shown that the spike protein connects to neuropilin-1 in the same region where VEGF-A is located. In the study, experts have used VEGF-A to trigger pain in rodents, later they have added the SARS-CoV-2 virus protein. Experts have seen that the spike protein has completely reversed the VEGF-A induced pain signaling process. Scientists have claimed that the new revelation can lead to new findings for pain mitigation in other ailments, which involve chronic pain. Researchers are planning to devise small molecules, which can block neuropilin-1 for pain relief. This study has been published in Pain magazine. Some past studies have shown that the SARS-CoV-2 virus can restrict the production of interferon as well, which robs off cells’ ability to delay the infection.

SHARE:
Kathleen Kinder

Kathleen Kinder

With over 4 years of experience in the research industry, Kathleen is generally engrossed in market consulting projects, catering primarily to domains such as ICT, Health & Pharma, and packaging. She is highly proficient in managing both B2C and B2B projects, with an emphasis on consumer preference analysis, key executive interviews, etc. When Kathleen isn’t deconstructing market performance trajectories, she can be found hanging out with her pet cat ‘Sniffles’.